Capricor Therapeutics Faces FDA Advisory Committee Meeting for Duchenne Drug Application
Capricor Therapeutics (CAPR) experienced a ~12% drop in stock price after the U.S. FDA announced an advisory committee meeting to review its marketing application for Deramiocel, a treatment for Duchenne muscular dystrophy.
Tickers: $CAPR